BVS Stock Summary and Trading Ideas (Bioventus - Class A | NASDAQ:BVS)

Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.

Bioventus - Class A trades on the NASDAQ stock market under the symbol BVS.

As of September 1, 2026, BVS stock price climbed to $13.67 with 619,311 million shares trading.

BVS has a beta of 0.65, meaning it tends to be less sensitive to market movements. BVS has a correlation of 0.04 to the broad based SPY ETF.

BVS has a market cap of $924.62 million. This is considered a Small Cap stock.

Last quarter Bioventus - Class A reported $153 million in Revenue and $.22 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.01.

In the last 3 years, BVS traded as high as $15.89 and as low as $2.82.

The top ETF exchange traded funds that BVS belongs to (by Net Assets): AVUV, IWM, VTI, VXF, IWO.

BVS has outperformed the market in the last year with a return of +84.7%, while the SPY ETF gained +19.3%. In the last 3 month period, BVS beat the market returning +60.6%, while SPY returned +1.0%. However, in the most recent 2 weeks BVS has underperformed the stock market by returning -1.5%, while SPY returned -1.4%.

BVS support price is $13.29 and resistance is $14.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BVS shares will trade within this expected range on the day.